Mark Abbott PhD

Managing Director

Mark is the founder and Managing Director of Peak Proteins. An enthusiast for science with extensive experience in protein and cell science and their application to discovery of both small molecule and biological drugs.

Mark Abbott PhD Chief Executive Officer | Peak Proteins

More about Mark

Mark is the founder and Managing Director of Peak Proteins. Prior to that he worked for over 20 years in the pharmaceutical industry as a protein biochemist in AstraZeneca. He led teams providing protein expression and purification expertise into drug discovery projects in multiple different research areas in both small molecule and biologics projects. He has managed both technology and biologics drug discovery projects within global Pharma.

Mark has always been an enthusiast for science and its application to progressing drug discovery projects. He has more than 30 peer reviewed publications on a very wide range of proteins and their use particularly in drug discovery. When not working Mark is often to be found on a bike commuting to work, riding for leisure up a hill in the Peak District or racing in a time trial, sadly a lot slower than a few years ago.

Heparan sulfates are critical regulators of the inhibitory megakaryocyte-platelet receptor G6b-B
Elife. 2019 8. pii: e46840
Vögtle T, Sharma S, Mori J, Nagy Z, Semeniak D, Scandola C, Geer MJ, Smith CW, Lane J, Pollack S, Lassila R, Jouppila A, Barr AJ, Ogg DJ, Howard TD, McMiken HJ, Warwicker J, Geh C, Rowlinson R, Abbott WM, Eckly A, Schulze H, Wright GJ, Mazharian A, Fütterer K, Rajesh S, Douglas MR, Senis YA.

Use of a Protein Engineering Strategy to Overcome Limitations in the Production of ‘Difficult to Express’ Recombinant Proteins
Biotechnolgy and Bioengineering 2017 114(10):2348-2359.
Hirra Hussain, David I Fisher, W Mark Abbott, Robert G Roth, Alan J Dickson

Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site
Nat Chem Biol.  2016 12, 815–821
Exell JC, Thompson MJ, Finger LD, Shaw SJ, Debreczeni J, Ward TA, McWhirter C, Siöberg CL, Molina DM, Abbott WM, Jones CD, Nissink JW, Durant ST, Grasby JA

Optimisation of a simple method to transiently transfect a CHO cell line in high-throughput and at large scale
Protein Expression and Purification 2015 116, 113–119.
Mark Abbott, Brian Middleton, Fredrik Kartberg, Josefine Claesson, Robert Roth, David Fisher

Current approaches to fine mapping of antigen antibody interactions.
Immunology 2014 142, 526–535.
WM Abbott, M Damschroder, DC Lowe

Characterization of the complex formed between a potent neutralizing ovine-derived polyclonal anti-TNFalpha Fab fragment and human TNFalpha.
Bioscience Reports 2013 33 e00060
WM Abbott, M Snow, S Eckersley, J Renshaw, G Davies, RA Norman, P Ceuppens, J Slootstra, JJ Benschop, Y Hamuro, JE Lee, P Newham

Co-expression of protein phosphatases in insect cells affects phosphorylation status and expression levels of proteins.
Protein Expression and Purification 2012 83, 217-225.
Brading RL, Abbott WM, Green I, Davies A, McCall EJ

Structure of IL-17A in complex with a potent, fully human neutralizing antibody.
J Mol Biol 2009 394(5):905-921.
Gerhardt S, Abbott WM, Hargreaves D, Pauptit RA, Davies RA, Langham C, Barker W, Aziz A, Snow MJ, Dawson S, Welsh F, Wilkinson T,Vaugan T, Beste G, Bishop S, Popovic B, Rees G, Sleeman M, Tuske SJ, Coales SJ, Hamuro Y, Russell C

Leadership Team